---
layout: default
title: Palivizumab
parent: 僅模型預測 (L5)
nav_order: 330
evidence_level: L5
indication_count: 10
---

# Palivizumab
{: .fs-9 }

證據等級: **L5** | 預測適應症: **10** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Palivizumab: From RSV Infection Prevention to Benign Neoplasm of Tongue

## One-Sentence Summary

Palivizumab is a humanized monoclonal antibody used for the prevention of respiratory syncytial virus (RSV) infection in high-risk infants. The TxGNN model predicts a possible link to **Benign Neoplasm of Tongue**, but this prediction is currently supported by **0 clinical trials** and **0 publications**, and the evidence pack itself flags the signal as a likely false positive.

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not on file in the Danish registry (drug not marketed); internationally used for RSV infection prophylaxis in high-risk infants |
| Predicted New Indication | Benign Neoplasm of Tongue |
| TxGNN Prediction Score | 99.94% |
| Evidence Level | L5 (model prediction only, no supporting studies) |
| Denmark Market Status | Not marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data for Palivizumab is not available in this evidence pack (recorded as a data gap). Based on general pharmacological knowledge referenced within the evidence pack's own repurposing rationale, Palivizumab is a humanized monoclonal antibody that targets the RSV fusion (F) protein, blocking viral fusion to provide passive immunoprophylaxis against RSV in high-risk infants — it is not an oncology agent and has no known target overlap with tumour biology.

The evidence pack's own mechanistic assessment explicitly states there is **no known biological relationship** between RSV-fusion-protein inhibition and benign neoplasm of the tongue. No shared pathway, target, or disease-family logic bridges the original antiviral indication to this predicted oncologic indication.

Notably, the top 10 predicted indications collapse into only 5 unique diseases (each duplicated), all clustered within a narrow score band (~0.9994–0.9999) and all belonging to the head/neck-tumour or neuroblastoma family. Combined with the fact that this drug node has no recorded DDIs, no original indications on file, and missing MOA data, this pattern is consistent with a **sparse-node embedding artifact** in the knowledge graph rather than a genuine pharmacological signal. This assessment is stated directly in the evidence pack's repurposing rationale and should be treated as a strong caution flag, not a promising lead.

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

---

## Literature Evidence

Currently no related literature available.

---

## Denmark Market Information

No marketing authorisations on file. Palivizumab currently holds **0 licenses** and is **not marketed** in Denmark according to this evidence pack.

---

## Safety Considerations

Please refer to the approved Summary of Product Characteristics (SmPC) for safety information. Note: key warnings, contraindications, and drug-drug interaction data are recorded as a **Blocking** data gap (DG001) in this evidence pack — safety evaluation cannot proceed to initial screening (S1) until this is resolved.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
- No mechanistic plausibility, no clinical trials, and no literature support the predicted link to benign neoplasm of the tongue; the evidence pack itself assesses this as a likely embedding-space false positive rather than a real signal.
- A Blocking data gap (missing SmPC warnings/contraindications) prevents any safety pre-screening, and the drug is not currently marketed in Denmark.

**To proceed, the following is needed:**
- Official MOA confirmation from DrugBank/SmPC
- TFDA/EMA-equivalent label data (warnings, contraindications) to resolve the Blocking data gap
- Independent biological rationale or preclinical data connecting RSV-antibody mechanism to head/neck neoplasm biology before this candidate is reconsidered
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

